SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited
May 03 2023 - 6:00AM
Business Wire
SOPHiA GENETICS expands footprint in India as
Unipath Specialty Laboratory Limited is now live on SOPHiA DDM™ HRD
Solution
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company
in the healthcare space and a leader in data-driven medicine, today
announced that Unipath Specialty Laboratory Limited, one of the
leading diagnostic brands in India, is live on the SOPHiA DDM™
Homologous Recombination Deficiency (HRD) Solution. Using SOPHiA
GENETICS’ technology, Unipath Specialty Laboratory Limited has
launched HRD Gene Panel, its latest offering in the field of cancer
genomics.
HRD is caused by a cell’s impaired ability to repair DNA
double-stranded breaks through the homologous recombination repair
(HRR) pathway and is linked with the development of certain
cancers, including advanced ovarian cancer. In India alone, the
incidence of ovarian cancer is expected to increase by 55 percent
by 2035, and the death rate is expected to increase by 67 percent
to approximately 254,000 patients1. Unipath Specialty Laboratory
Limited will utilize SOPHiA GENETICS’ innovative SOPHiA DDM™
Platform and SOPHiA HRD Solution to implement HRD testing via its
new HRD Gene Panel, thereby advancing cancer research in India.
“We’re very impressed by how SOPHiA GENETICS simplifies the
entire process of data analysis with extreme accuracy. They not
only provide the level of information and reporting that we
require, but they go above and beyond to offer in-depth analysis
that can better inform our clinicians and help them make
data-driven decisions,” said Dr. Neeraj Arora, Director, Molecular
Genetics, at Unipath Specialty Laboratory Limited. “Through the use
of the SOPHiA DDM™ HRD Solution, Unipath Specialty Laboratory
Limited will enhance its genetic testing capabilities, improve
disease research, and better serve the population in India.”
The SOPHiA DDM™ HRD Solution will enable Unipath Specialty
Laboratory Limited to retain full ownership of their data, saving
time and expense, while offering comprehensive genomic insights
powered by deep learning algorithms.
“The implementation of the SOPHiA DDM™ HRD Solution by Unipath
Specialty Laboratory Limited is expected to help with the
incremental expansion of HRD research into India and the increase
of data diversity, furthering our goal at SOPHiA GENETICS of making
data-driven medicine more accessible globally,” said Ken Freedman,
Chief Revenue Officer, SOPHiA GENETICS. “We look forward to seeing
how this collaboration will advance cancer research and support the
work of Unipath Specialty Laboratory Limited in serving the vast
community in India.”
Unipath Specialty Laboratory Limited is spread across India with
40 labs in 11 states. Currently, Unipath Specialty Laboratory
Limited conducts more than 5 million laboratory tests annually. By
leveraging the SOPHiA GENETICS DDM™ Platform, Unipath Specialty
Laboratory Limited will have the potential to analyze molecular
data with more efficiency, saving precious time and expensive lab
costs.
In addition to implementing the SOPHiA DDM™ HRD Solution,
Unipath Specialty Laboratory Limited will utilize SOPHiA GENETICS’
exome analysis services with both whole and clinical exome
solutions, which is expected to support the identification of
indication-based variants in less time with better accuracy.
For more information on SOPHiA GENETICS, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and
Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook, and Instagram. Where
others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management’s beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
About Unipath Specialty Laboratory Limited
Unipath Specialty Laboratory Limited is a state-of-the-art
facility offering end-to-end solutions. Ingrained in 2009 at
Ahmedabad in India, Unipath Specialty Laboratory Limited launched
its services in Pathology and Molecular Genetics. With a mission to
be a global leader in genomics Unipath Specialty Laboratory Limited
continued to evolve its infrastructure and test services for
molecular biology, cytogenetics and advanced genomics across India
to help clinicians, scientists, researchers in better clinical
diagnosis, discover new and more personalized drugs and better
disease management.
1
https://aujmsr.com/global-scenario-on-ovarian-cancer-its-dynamics-relative-survival-treatment-and-epidemiology-2/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005357/en/
Media: Kelly Katapodis kkatapodis@sophiagenetics.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024